NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET
Company Participants
Matthew Duffy – Chief Business Officer
Jonathan Javitt – Founder, Chairman and Chief Scientist
Michael Abrams – Chief Financial Officer
Conference Call Participants
Jason Kolbert – D. Boral Capital
Thomas Shrader – BTIG
Vernon Bernardino – H.C. Wainwright
Ed Woo – Ascendiant Capital
Operator
Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Monday, March, 17 2025.
I would now like to turn the conference over to Matthew Duffy, Chief Business Officer. Please go ahead.
Matthew Duffy
Thank you, Joelle, and good morning, everyone. Welcome to our call.
Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U. S. Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made during this call speak only as of the day hereof, and the company undertakes no obligation to update or revise the forward looking statements.
Information presented on this call is contained in the press release issued this morning and the company’s Form 10-K, which was filed on Friday and may be accessed from the Investor page of the NRx Pharmaceuticals, Inc. website.
Joining me today on the call are Jonathan Javitt, our Founder, Chairman and CEO; and
#NRx #Pharmaceuticals #NRXP #Earnings #Call #Transcript